STOCK TITAN

ContraFect Corporation - CFRX STOCK NEWS

Welcome to our dedicated news page for ContraFect Corporation (Ticker: CFRX), a resource for investors and traders seeking the latest updates and insights on ContraFect Corporation.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ContraFect Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ContraFect Corporation's position in the market.

Rhea-AI Summary
ContraFect Corporation announces presentation at ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
conferences
-
Rhea-AI Summary
ContraFect submits IND application for CF-370 to FDA for treatment of HABP/VABP, positive milestone for the company
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.06%
Tags
-
Rhea-AI Summary
ContraFect to present updated overview of DLA programs targeting antibiotic-resistant pathogens at AMR Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
ContraFect Corporation announces business updates and financial results for Q2 2023. They are on track to file an IND for CF-370 in Q3. Multiple studies show efficacy of CF-370 against Gram-negative pathogens. New data supports DLAs as potential therapies for infections. Received $9.6M from exercise of common stock purchase warrants. R&D expenses decreased to $4.9M. Net loss was $7.6M for Q2 2023. Cash and cash equivalents of $14.4M as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.72%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12%
Tags
-
ContraFect Corporation

Nasdaq:CFRX

CFRX Rankings

CFRX Stock Data

535.24k
10.69M
0.65%
6.13%
2.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Yonkers

About CFRX

we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba